Table 1 |
||||||
|
Characteristics of the patients. IVDU: intravenous drug user |
||||||
|
PATIENT |
SEX |
AGE |
RISK FACTORS |
EPISODES* |
EVIDENCE OF NON-ADHERENCE TO THERAPY |
CLONAL HETEROGENEITY |
|
|
||||||
|
A |
Female |
44 |
9 (4) |
+ |
+ |
|
|
B |
Male |
50 |
IVDU |
2 |
+ |
|
|
C |
Male |
46 |
4 (2) |
|||
|
D |
Male |
45 |
HIV+, IVDU, Prison |
2 |
+ |
|
|
E |
Male |
28 |
3 |
+ |
||
|
F |
Male |
57 |
Alcoholism |
4 (3) |
||
|
G |
Male |
52 |
Alcoholism |
2 |
+ |
|
|
H |
Male |
32 |
HIV+, IVDU |
4 |
+ |
|
|
I |
Female |
31 |
HIV+, IVDU |
2 |
+ |
|
|
J |
Male |
46 |
HIV+, IVDU |
2 |
+ |
|
|
K |
Male |
46 |
HIV+, Alcoholism |
2 |
+ |
|
|
L |
Male |
53 |
IVDU, Alcoholism, Prison |
3 (2) |
+ |
|
|
M |
Male |
53 |
2 |
|||
|
|
||||||
|
*: The number of episodes with MTB isolates that could be analyzed by MIRU-VNTR are indicated in brackets. |
||||||
|
MartÃn et al. BMC Microbiology 2007 7:73 doi:10.1186/1471-2180-7-73 |
||||||